Written by
Clinical Laboratories: Key Partners in the Battle Against Alzheimer’s Disease
Alzheimer’s disease remains one of the most significant global health challenges, affecting millions of individuals and families worldwide. Recent advancements highlighted at the Neuroimmunology in Drug Discovery forum in Boston signal meaningful progress across Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis. At the center of these advances are clinical laboratories, working in close collaboration with pharmaceutical, biotech, and healthcare organizations to deliver the diagnostic insights necessary for earlier detection, more efficient clinical trials, and improved patient outcomes.
Laboratories at the Forefront of Diagnostic Innovation
One of the most consequential shifts in Alzheimer’s care is the FDA clearance of blood-based diagnostic tests, marking a departure from historically invasive, costly, and less accessible approaches such as PET imaging and lumbar punctures (FDA, 2025).
In early 2026, Labcorp announced the nationwide availability of the Elecsys® pTau-181 test, the first and only FDA-cleared blood test approved to aid in the initial assessment of Alzheimer’s disease in primary care settings (PR Newswire, 2026). This milestone represents a critical transition—from academic validation and specialist use to real-world clinical deployment at scale.
Primary care clinicians are often the first point of contact for patients experiencing cognitive symptoms, yet historically have lacked accessible tools to assess Alzheimer’s pathology. The Elecsys pTau-181 test addresses this gap by helping clinicians rule out Alzheimer’s disease in symptomatic patients aged 55 and older by identifying those unlikely to have amyloid pathology. Patients with negative results can be evaluated for alternative causes of cognitive decline, while positive results can be referred for confirmatory testing and specialist care.
Health systems and academic institutions such as Mount Sinai and Mayo Clinic Laboratories have also begun implementing blood-based Alzheimer’s diagnostics, reinforcing the role of laboratories in expanding access to earlier, more equitable diagnosis and reducing delays in care (San Francisco Chronicle, 2025).
Understanding Early Markers: Inflammation and Aging
At the Boston forum, Cheryl Leyns, PhD, of Merck Research Laboratories emphasized that neuroinflammation often precedes clinical symptoms of neurodegenerative disease. Her research focuses on inhibitors targeting the NLRP3 protein, a key driver of inflammatory pathways implicated in Alzheimer’s disease (Wallask, 2025).
Complementing this work, senior postdoctoral fellow Rebecca Wailings highlighted the importance of studying aging immune systems. As immune function declines with age, susceptibility to chronic inflammation increases—further accelerating the onset and progression of neurodegenerative disease (Wallask, 2025). These insights reinforce the importance of earlier diagnostic intervention, where laboratory testing plays a foundational role.
Beyond Alzheimer’s: Expanding Diagnostic Frontiers
Innovation in laboratory diagnostics extends beyond Alzheimer’s disease. Emerging research demonstrates the use of AI-enabled diagnostic tools to detect early Parkinson’s disease through unconventional biomarkers, such as earwax analysis, showcasing the expanding scope of non-invasive diagnostics (New York Post, 2025).
Internationally, the UK’s NHS is also evaluating blood-based tests for early dementia detection, underscoring the growing global reliance on laboratories to support scalable, early-stage neurological assessment (The Sun, 2025).
Clinical Laboratories as Catalysts for Healthcare Transformation
Clinical laboratories are not only transforming diagnosis—they are accelerating therapeutic development. By enabling more precise patient selection and stratification for clinical trials, laboratories help reduce development timelines and improve the efficiency of therapeutic validation (Mayo Clinic Laboratories, 2025).
With Alzheimer’s prevalence projected to double by 2050, scalable diagnostic solutions are no longer optional. Blood-based tests—particularly those deployable in primary care—will be essential for addressing growing demand while navigating ongoing specialist shortages and healthcare access constraints (FDA, 2025; PR Newswire, 2026).
Looking Ahead: Collaboration as the Path Forward
The partnership between clinical laboratories, pharmaceutical developers, and healthcare providers remains essential to progress in neurodegenerative disease care. As biomarkers evolve and diagnostics become more accessible, laboratories will continue to enable earlier intervention, more personalized treatment pathways, and improved quality of life for patients.
Clinical laboratories are no longer operating behind the scenes. They are leaders in the transformation of Alzheimer’s care, shaping how disease is identified, studied, and managed across the healthcare continuum.
Empowering the Future of Neurological Care through Laboratory Leadership
As the battle against Alzheimer's disease and other neurodegenerative conditions intensifies, clinical laboratories are emerging as central catalysts—driving diagnostic innovation, enabling therapeutic breakthroughs, and transforming the future of neurological care. Through strategic collaboration, an unwavering commitment to quality, and the agility to lead through change, laboratories and their healthcare partners are poised to revolutionize how we detect, treat, and ultimately prevent some of the most devastating diseases of our time. With cutting-edge quality management systems like MediaLab by Vastian empowering this transformation, the path forward is filled with promise and possibility. To learn how we can support your organization's neurodegenerative diagnostics initiatives, request a demo today.
References
- FDA News Release. “FDA clears first blood test used for diagnosing Alzheimer’s disease.” May 2025. [Link]
- PR Newswire. “Labcorp Launches First FDA-Cleared Blood Test for Alzheimer’s Disease Assessment in Primary Care.” Feb. 11, 2026.
- Wallask, Scott. “Clinical Laboratories and Drug Discovery Firms Act in Parallel against Alzheimer’s Disease.” Dark Daily, June 30, 2025. [Link]
- San Francisco Chronicle. “New Alzheimer’s blood tests make diagnosis easier.” June 2025. [Link]
- New York Post. “Earwax could offer clues of early Parkinson’s disease.” June 2025.
- The Sun. “Blood tests for early dementia detection trials by NHS.” June 2025. [Link]
- Mayo Clinic Laboratories. “Advances in Neurodegenerative Disease Diagnostics.” March 2025. [Link]
Disclaimer
This article includes brief excerpts and references to external sources. All references and direct quotes are clearly attributed and linked to the original content.